Healthcare tech company GoodRx (NASDAQ: GDRX) will be reporting earnings this Wednesday after the bell. Here’s what to expect.

GoodRx met analysts’ revenue expectations last quarter, reporting revenues of $203 million, up 2.6% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and a significant miss of analysts’ customer base estimates. It lost -200,000 customers and ended up with a total of 6.4 million.

Is GoodRx a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting GoodRx’s revenue to grow 2.5% year on year to $205.7 million, slowing from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GoodRx has missed Wall Street’s revenue estimates twice over the last two years.

Looking at GoodRx’s peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts’ expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell’s stock price was unchanged following the results.

Read our full analysis of Hims & Hers Health’s results here and Omnicell’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. GoodRx is down 4.6% during the same time and is heading into earnings with an average analyst price target of $6.32 (compared to the current share price of $4.52).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.